Overview: LECT2 TestIntroduction: The LECT2 Test detects LECT2 protein to diagnose amyloidosis, causing organ dysfunction or swelling. Following 2023 International Amyloidosis Society guidelines, it uses histopathology for high specificity, supporting renal screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected LECT2 amyloidosis.
Other Names: LECT2 Amyloid Assay, Amyloidosis IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: LECT2 amyloid testing began in the 2000s with amyloidosis research. Immunohistochemistry methods improved diagnostic precision.
Purpose: Detects LECT2 protein to diagnose amyloidosis, guides treatment, and evaluates patients with organ dysfunction or swelling.
Test Parameters: 1. LECT2 Protein
Pretest Condition: No fasting required. Collect tissue. Report history of organ dysfunction, swelling, or amyloidosis symptoms.
Specimen: Tissue (FFPE, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document organ dysfunction, swelling, renal issues, or family history of amyloidosis. Include current medications, especially immunosuppressive therapy.
Consent: Written consent required, detailing the tests purpose, amyloidosis implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect LECT2 protein in tissue. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for amyloidosis diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or low tissue quality can affect results. Contamination may reduce specificity.
Clinical Significance: Positive LECT2 staining confirms LECT2 amyloidosis, guiding supportive care or organ-specific therapy. Negative results may require further amyloid testing.
Specialist Consultation: Consult a nephrologist or hematologist for result interpretation and treatment planning.
Additional Supporting Tests: Congo red staining, serum amyloid A, or renal biopsy to confirm amyloidosis diagnosis.
Test Limitations: Not specific to LECT2 amyloidosis; other amyloid types may require additional testing. Clinical correlation is needed.
References: International Amyloidosis Society Guidelines, 2023; Kidney International, Benson MD, 2022.
